Categories
Articles

Abstract

Abstract
 
Vol 48 No. 2: 174-181 [PDF] [Full Text]
 
MicroRNA-140 regulates cell growth and invasion in pancreatic duct adenocarcinoma by targeting iASPP
 
Shuai Liang,

Xuejun Gong,

Gewen Zhang,

Gengwen Huang,

Yebin Lu and

Yixiong Li*

 
Department of Pancreatic Biliary Surgery, Xiangya Hospital, Central South University, Changsha 410008, China
 

Abstract  Received June 15, 2015.

Accepted November 21, 2015.

MicroRNAs are ∼22 nucleotide RNAs processed from RNA hairpin structures that play important roles in regulating protein expression level via binding to mRNA, either suppressing its translation or speeding up its degradation. In humans, they regulate most protein-coding genes, including genes important in cancer and other diseases. In this study, the expression of microRNA-140 (miR-140) was demonstrated to be significantly suppressed in pancreatic duct adenocarcinoma specimens and cell lines, compared with their adjacent normal tissues. With the help of bioinformatics analysis, inhibitor of apoptosis-stimulating protein of p53 (iASPP) was identified to be a direct target of miR-140, and luciferase reporter experiment confirmed this discovery. Overexpression of miR-140 decreases the protein expressions of iASPP, ΔNp63, MMP2, and MMP9. Growth and invasion of PANC-1 cells were attenuated by overexpression of miR-140 in vitro. The suppressive effect of miR-140 on PANC-1 cell line could be partly balanced out by manual overexpression of iASPP. Above all, these findings provided insights into the functional mechanism of miR-140, suggested that the miR-140/iASPP axis may interfere with the proliferative and invasive property of pancreatic duct adenocarcinoma cells, and indicated that miR-140 could be a potential therapeutic target for pancreatic duct adenocarcinoma.

 

Keywords   miR-140; pancreatic duct adenocarcinoma; cell proliferation; cell invasion; iASPP

 

Received   2015-6-15  

Accepted  2015-11-21

 

Funding  –

 

* Correspondence address  Tel: +86-13787271131; Fax: +86-0731-89932501; E-mail: [email protected]

 
Browse:232